H1N1 Vaccines Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines), By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition Forecast & Opportunities, 2018-2028F
Global H1N1 Vaccines Market has valued at USD 9910.85 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.23% through 2028. The global H1N1 vaccines market is a crucial component of the healthcare industry, primarily focused on preventing and controlling the spread of the H1N1 influenza virus, commonly known as swine flu.
Key Market Drivers
Pandemic Preparedness and Awareness
The memory of the 2009 H1N1 influenza pandemic serves as a stark reminder of the devastating consequences that a widespread outbreak can have on public health and the global economy. This historical context has led to a heightened sense of urgency in pandemic preparedness.
Governments around the world have recognized the critical role of vaccination in pandemic response. As a result, they have allocated substantial resources to support the development, production, and distribution of H1N1 vaccines. This financial backing is instrumental in boosting the growth of the vaccines market.
Heightened pandemic awareness has accelerated vaccine development processes. Regulatory agencies have implemented expedited approval pathways for vaccines during emergencies, enabling quicker market entry for H1N1 vaccines. This agility in response benefits both vaccine manufacturers and public health.
Pandemic preparedness includes continuous surveillance and monitoring of influenza strains, including H1N1. Vigilance in tracking the virus's evolution ensures that vaccines are updated to match circulating strains, maintaining their effectiveness.
Governments and international organizations have created vaccine stockpiles as part of their pandemic preparedness strategies. This strategic stockpiling of H1N1 vaccines ensures that there are sufficient doses available in the event of an outbreak, thus creating a consistent demand for vaccine manufacturers.
Heightened awareness of pandemic risks, coupled with effective public health campaigns, encourages individuals to get vaccinated. These campaigns educate the public about the importance of vaccination in preventing and mitigating the spread of H1N1 influenza.
Global organizations such as the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) facilitate international collaboration in pandemic preparedness. This collaborative effort enhances vaccine research, development, and equitable distribution, contributing to market growth.
Continual Virus Monitoring and Evolution
The H1N1 influenza virus exhibits remarkable genetic diversity, leading to the emergence of new strains over time. By continually monitoring these genetic changes, researchers and vaccine manufacturers can adapt vaccine formulations to match the prevalent strains, ensuring vaccine efficacy.
Real-time virus monitoring enables a swift response to the emergence of novel H1N1 strains. This agility in vaccine development and production is crucial in mitigating the impact of potential outbreaks, which, in turn, bolsters the demand for H1N1 vaccines.
As H1N1 viruses evolve, the vaccines must keep pace. Up-to-date vaccines that target the most prevalent strains are more effective in preventing infection, reducing illness severity, and limiting virus transmission. This enhanced effectiveness incentivizes individuals to get vaccinated.
The need for constant adaptation to evolving H1N1 strains drives research and development investments in the field of influenza vaccines. Pharmaceutical companies allocate resources to develop and test new vaccine formulations, fostering innovation in the H1N1 vaccines market.
Regulatory agencies recognize the importance of staying ahead of evolving influenza strains. They often provide expedited approval pathways for updated vaccine formulations during outbreaks or when new variants emerge. This flexibility expedites market entry for vaccine manufacturers.
Global collaboration is instrumental in virus monitoring and vaccine development. International organizations, such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), work together to track influenza strains and share data. This collaboration promotes a coordinated global response and ensures equitable access to vaccines.
Public Health Initiatives
Public health initiatives play a crucial role in raising awareness about the risks associated with H1N1 influenza. By educating the public about the importance of vaccination and the potential consequences of not getting vaccinated, these initiatives create a more informed and motivated populace.
Vaccine hesitancy, fueled by misinformation and mistrust, can hinder vaccination efforts. Public health campaigns are designed to combat vaccine hesitancy by providing accurate information, addressing concerns, and building confidence in the safety and efficacy of H1N1 vaccines.
Public health initiatives often focus on identifying and targeting high-risk populations, such as the elderly, young children, pregnant women, and individuals with underlying health conditions. Encouraging vaccination among these vulnerable groups is essential in reducing severe illness and mortality, thus driving demand for H1N1 vaccines.
Many public health agencies run annual seasonal vaccination campaigns. These campaigns coincide with the flu season and remind the public to get vaccinated against H1N1 and other influenza strains. This regularity in campaigns sustains market demand.
Governments and healthcare organizations often subsidize or provide H1N1 vaccines free of charge to eligible populations. This financial support makes vaccines more accessible to a broader segment of the population, increasing vaccination rates and market demand.
Public health initiatives frequently involve community outreach efforts. Mobile vaccination clinics, partnerships with schools and workplaces, and community-based awareness programs make it convenient for individuals to access H1N1 vaccines.
International organizations like the World Health Organization (WHO) work with governments and health agencies globally to coordinate vaccination efforts. These partnerships ensure that vaccines reach underserved populations, driving global demand.
Advancements in Vaccine Technology
One of the most significant advancements in vaccine technology is the development of novel platforms for H1N1 vaccines. Traditional vaccines were typically based on inactivated or weakened forms of the virus. However, modern technologies, such as recombinant DNA and mRNA, have enabled the creation of safer and more effective vaccines.
Advancements in vaccine technology have led to vaccines with improved safety profiles. Newer vaccines are often designed to minimize adverse reactions while still providing robust protection against H1N1 influenza. This increased safety instills greater public confidence in vaccination.
Modern vaccine platforms are engineered to enhance the body's immune response to H1N1 antigens. This means that individuals receiving these vaccines develop stronger and longer-lasting immunity, reducing the likelihood of infection and transmission.
Advanced vaccine technologies allow for precise selection of antigens that match the circulating H1N1 strains. This targeted approach ensures that vaccines are highly effective against the specific strains causing illness, boosting consumer trust in their efficacy.
Traditional vaccine development processes could be time-consuming. However, advancements like mRNA vaccine technology have streamlined the development and production of H1N1 vaccines. Faster production timelines can better meet demand during outbreaks.
Emerging technologies in vaccine development open the door to personalized vaccines. These vaccines can be tailored to an individual's genetic makeup, optimizing their immune response and overall protection against H1N1.
Innovative adjuvants and formulation techniques have been developed to enhance vaccine effectiveness. These technologies can increase the body's response to the vaccine, allowing for lower vaccine doses while maintaining high efficacy.
Some advancements focus on improving vaccine storage and distribution. Technologies like freeze-drying and improved cold chain logistics ensure that vaccines remain viable, even in remote or resource-constrained areas, expanding market reach.
Key Market Challenges
Virus Mutations and Evolution
Perhaps the most significant challenge in the H1N1 vaccines market is the constant evolution of the virus. H1N1 influenza strains mutate regularly, making it necessary to update vaccine formulations to match the currently circulating strains. This requires ongoing research, surveillance, and timely adjustments in vaccine production.
Vaccine Production Capacity
Scaling up vaccine production to meet demand during outbreaks can be a logistical challenge. Vaccine manufacturing facilities need to be agile and capable of producing sufficient doses within a short timeframe. Ensuring an adequate supply of vaccines during an outbreak is a priority.
Cold Chain Logistics
Maintaining the cold chain during the storage and distribution of vaccines is critical to their effectiveness. In regions with limited infrastructure, maintaining the required temperature range can be challenging. Investments in cold chain logistics are essential to overcome this hurdle.
Key Market Trends
Universal Influenza Vaccines
One of the most promising trends in the H1N1 vaccines market is the development of universal influenza vaccines. These vaccines aim to provide broad protection against multiple influenza strains, including H1N1. By targeting conserved components of the virus, universal vaccines have the potential to reduce the need for annual updates and improve long-term immunity.
mRNA Vaccine Technology
The success of mRNA vaccine technology in combatting COVID-19 has generated considerable interest in its application to other infectious diseases, including H1N1. mRNA vaccines offer a rapid response to emerging strains, enabling quicker adaptation to changing virus dynamics. The adoption of mRNA platforms in H1N1 vaccine development is expected to gain momentum.
Cross-Protection Against Zoonotic Strains
H1N1 influenza has a zoonotic origin, making it crucial to monitor and address potential spillover events from animals to humans. Upcoming trends may include the development of H1N1 vaccines with cross-protective capabilities against zoonotic strains, reducing the risk of future pandemics.
Segmental Insights
Route of Administration Insights
Based on the category of Route of Administration, it is projected that the Intramuscular Vaccines sector will experience a substantial surge in growth. Intramuscular injections are a method employed to administer medication deep into the muscles, facilitating rapid absorption into the bloodstream. This mode of injection offers swifter absorption compared to subcutaneous injections, owing to the muscles' superior blood supply in comparison to the tissue beneath the skin. Furthermore, muscle tissue has the capacity to accommodate a larger volume of medication than subcutaneous tissue.
According to a 2017 United Nations report, the global population is aging at an annual rate of 3%, leading to an increased susceptibility to various ailments such as respiratory tract disorders and immune deficiencies. Consequently, the risk of infection from the H1N1 virus is on the rise.
The Intramuscular Vaccines segment currently commands a significant share of the H1N1 vaccines market and is expected to maintain a similar trajectory throughout the forecast period. This can be attributed to the escalating incidence of swine flu and the growing demand for H1N1 vaccinations, particularly among the elderly population who face an elevated risk of respiratory and immune-related conditions.
Distribution Channel Insights
Hospital pharmacies are poised to dominate the Global H1N1 Vaccines Market for several compelling reasons. Firstly, hospitals are strategically positioned as healthcare hubs that cater to a wide spectrum of patients, including those in high-risk groups. This ensures a substantial and consistent demand for H1N1 vaccines. Secondly, hospital pharmacies possess the necessary infrastructure and expertise to store and administer vaccines efficiently, adhering to stringent regulatory standards. This instills confidence in patients and healthcare providers alike, boosting the credibility of hospital pharmacies as reliable sources for vaccination. Additionally, hospitals often collaborate with government health agencies and insurance providers, facilitating wider access and affordability for patients. This, in turn, further solidifies their dominance in the H1N1 vaccines market. Lastly, hospitals can leverage their established healthcare networks to conduct outreach and vaccination campaigns, driving greater vaccination coverage and ultimately exerting a significant influence over the market's dynamics.
Regional Insights
In 2022, North America commands a substantial market share in the H1N1 vaccines sector, and this trend is expected to persist during the forecast period. This expectation is rooted in the region's proactive governmental efforts to prevent H1N1 infections and its well-developed research infrastructure. As per data from the Centers for Disease Control (CDC), roughly 8 percent of the U.S. population falls ill with influenza, leading to approximately 31.4 million doctor visits and 200,000 hospitalizations during each flu season. Furthermore, ongoing technological advancements in the field of vaccines, coupled with the presence of a robust healthcare infrastructure, are acting as catalysts for significant growth in the overall regional market.
Key Market Players
AstraZeneca PLC
Sanofi Pasteur MSD AG
GSK PLC
Abbott Laboratories Inc
CSL Ltd
Pfizer Inc
CPL Biologicals Pvt Ltd
Mitsubishi Tanabe Pharma Corp
Sinovac Biotech Co Ltd
Zydus Lifesciences Ltd
Report Scope:
In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.
Available Customizations:
Global H1N1 Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
Pandemic Preparedness and Awareness
The memory of the 2009 H1N1 influenza pandemic serves as a stark reminder of the devastating consequences that a widespread outbreak can have on public health and the global economy. This historical context has led to a heightened sense of urgency in pandemic preparedness.
Governments around the world have recognized the critical role of vaccination in pandemic response. As a result, they have allocated substantial resources to support the development, production, and distribution of H1N1 vaccines. This financial backing is instrumental in boosting the growth of the vaccines market.
Heightened pandemic awareness has accelerated vaccine development processes. Regulatory agencies have implemented expedited approval pathways for vaccines during emergencies, enabling quicker market entry for H1N1 vaccines. This agility in response benefits both vaccine manufacturers and public health.
Pandemic preparedness includes continuous surveillance and monitoring of influenza strains, including H1N1. Vigilance in tracking the virus's evolution ensures that vaccines are updated to match circulating strains, maintaining their effectiveness.
Governments and international organizations have created vaccine stockpiles as part of their pandemic preparedness strategies. This strategic stockpiling of H1N1 vaccines ensures that there are sufficient doses available in the event of an outbreak, thus creating a consistent demand for vaccine manufacturers.
Heightened awareness of pandemic risks, coupled with effective public health campaigns, encourages individuals to get vaccinated. These campaigns educate the public about the importance of vaccination in preventing and mitigating the spread of H1N1 influenza.
Global organizations such as the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI) facilitate international collaboration in pandemic preparedness. This collaborative effort enhances vaccine research, development, and equitable distribution, contributing to market growth.
Continual Virus Monitoring and Evolution
The H1N1 influenza virus exhibits remarkable genetic diversity, leading to the emergence of new strains over time. By continually monitoring these genetic changes, researchers and vaccine manufacturers can adapt vaccine formulations to match the prevalent strains, ensuring vaccine efficacy.
Real-time virus monitoring enables a swift response to the emergence of novel H1N1 strains. This agility in vaccine development and production is crucial in mitigating the impact of potential outbreaks, which, in turn, bolsters the demand for H1N1 vaccines.
As H1N1 viruses evolve, the vaccines must keep pace. Up-to-date vaccines that target the most prevalent strains are more effective in preventing infection, reducing illness severity, and limiting virus transmission. This enhanced effectiveness incentivizes individuals to get vaccinated.
The need for constant adaptation to evolving H1N1 strains drives research and development investments in the field of influenza vaccines. Pharmaceutical companies allocate resources to develop and test new vaccine formulations, fostering innovation in the H1N1 vaccines market.
Regulatory agencies recognize the importance of staying ahead of evolving influenza strains. They often provide expedited approval pathways for updated vaccine formulations during outbreaks or when new variants emerge. This flexibility expedites market entry for vaccine manufacturers.
Global collaboration is instrumental in virus monitoring and vaccine development. International organizations, such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), work together to track influenza strains and share data. This collaboration promotes a coordinated global response and ensures equitable access to vaccines.
Public Health Initiatives
Public health initiatives play a crucial role in raising awareness about the risks associated with H1N1 influenza. By educating the public about the importance of vaccination and the potential consequences of not getting vaccinated, these initiatives create a more informed and motivated populace.
Vaccine hesitancy, fueled by misinformation and mistrust, can hinder vaccination efforts. Public health campaigns are designed to combat vaccine hesitancy by providing accurate information, addressing concerns, and building confidence in the safety and efficacy of H1N1 vaccines.
Public health initiatives often focus on identifying and targeting high-risk populations, such as the elderly, young children, pregnant women, and individuals with underlying health conditions. Encouraging vaccination among these vulnerable groups is essential in reducing severe illness and mortality, thus driving demand for H1N1 vaccines.
Many public health agencies run annual seasonal vaccination campaigns. These campaigns coincide with the flu season and remind the public to get vaccinated against H1N1 and other influenza strains. This regularity in campaigns sustains market demand.
Governments and healthcare organizations often subsidize or provide H1N1 vaccines free of charge to eligible populations. This financial support makes vaccines more accessible to a broader segment of the population, increasing vaccination rates and market demand.
Public health initiatives frequently involve community outreach efforts. Mobile vaccination clinics, partnerships with schools and workplaces, and community-based awareness programs make it convenient for individuals to access H1N1 vaccines.
International organizations like the World Health Organization (WHO) work with governments and health agencies globally to coordinate vaccination efforts. These partnerships ensure that vaccines reach underserved populations, driving global demand.
Advancements in Vaccine Technology
One of the most significant advancements in vaccine technology is the development of novel platforms for H1N1 vaccines. Traditional vaccines were typically based on inactivated or weakened forms of the virus. However, modern technologies, such as recombinant DNA and mRNA, have enabled the creation of safer and more effective vaccines.
Advancements in vaccine technology have led to vaccines with improved safety profiles. Newer vaccines are often designed to minimize adverse reactions while still providing robust protection against H1N1 influenza. This increased safety instills greater public confidence in vaccination.
Modern vaccine platforms are engineered to enhance the body's immune response to H1N1 antigens. This means that individuals receiving these vaccines develop stronger and longer-lasting immunity, reducing the likelihood of infection and transmission.
Advanced vaccine technologies allow for precise selection of antigens that match the circulating H1N1 strains. This targeted approach ensures that vaccines are highly effective against the specific strains causing illness, boosting consumer trust in their efficacy.
Traditional vaccine development processes could be time-consuming. However, advancements like mRNA vaccine technology have streamlined the development and production of H1N1 vaccines. Faster production timelines can better meet demand during outbreaks.
Emerging technologies in vaccine development open the door to personalized vaccines. These vaccines can be tailored to an individual's genetic makeup, optimizing their immune response and overall protection against H1N1.
Innovative adjuvants and formulation techniques have been developed to enhance vaccine effectiveness. These technologies can increase the body's response to the vaccine, allowing for lower vaccine doses while maintaining high efficacy.
Some advancements focus on improving vaccine storage and distribution. Technologies like freeze-drying and improved cold chain logistics ensure that vaccines remain viable, even in remote or resource-constrained areas, expanding market reach.
Key Market Challenges
Virus Mutations and Evolution
Perhaps the most significant challenge in the H1N1 vaccines market is the constant evolution of the virus. H1N1 influenza strains mutate regularly, making it necessary to update vaccine formulations to match the currently circulating strains. This requires ongoing research, surveillance, and timely adjustments in vaccine production.
Vaccine Production Capacity
Scaling up vaccine production to meet demand during outbreaks can be a logistical challenge. Vaccine manufacturing facilities need to be agile and capable of producing sufficient doses within a short timeframe. Ensuring an adequate supply of vaccines during an outbreak is a priority.
Cold Chain Logistics
Maintaining the cold chain during the storage and distribution of vaccines is critical to their effectiveness. In regions with limited infrastructure, maintaining the required temperature range can be challenging. Investments in cold chain logistics are essential to overcome this hurdle.
Key Market Trends
Universal Influenza Vaccines
One of the most promising trends in the H1N1 vaccines market is the development of universal influenza vaccines. These vaccines aim to provide broad protection against multiple influenza strains, including H1N1. By targeting conserved components of the virus, universal vaccines have the potential to reduce the need for annual updates and improve long-term immunity.
mRNA Vaccine Technology
The success of mRNA vaccine technology in combatting COVID-19 has generated considerable interest in its application to other infectious diseases, including H1N1. mRNA vaccines offer a rapid response to emerging strains, enabling quicker adaptation to changing virus dynamics. The adoption of mRNA platforms in H1N1 vaccine development is expected to gain momentum.
Cross-Protection Against Zoonotic Strains
H1N1 influenza has a zoonotic origin, making it crucial to monitor and address potential spillover events from animals to humans. Upcoming trends may include the development of H1N1 vaccines with cross-protective capabilities against zoonotic strains, reducing the risk of future pandemics.
Segmental Insights
Route of Administration Insights
Based on the category of Route of Administration, it is projected that the Intramuscular Vaccines sector will experience a substantial surge in growth. Intramuscular injections are a method employed to administer medication deep into the muscles, facilitating rapid absorption into the bloodstream. This mode of injection offers swifter absorption compared to subcutaneous injections, owing to the muscles' superior blood supply in comparison to the tissue beneath the skin. Furthermore, muscle tissue has the capacity to accommodate a larger volume of medication than subcutaneous tissue.
According to a 2017 United Nations report, the global population is aging at an annual rate of 3%, leading to an increased susceptibility to various ailments such as respiratory tract disorders and immune deficiencies. Consequently, the risk of infection from the H1N1 virus is on the rise.
The Intramuscular Vaccines segment currently commands a significant share of the H1N1 vaccines market and is expected to maintain a similar trajectory throughout the forecast period. This can be attributed to the escalating incidence of swine flu and the growing demand for H1N1 vaccinations, particularly among the elderly population who face an elevated risk of respiratory and immune-related conditions.
Distribution Channel Insights
Hospital pharmacies are poised to dominate the Global H1N1 Vaccines Market for several compelling reasons. Firstly, hospitals are strategically positioned as healthcare hubs that cater to a wide spectrum of patients, including those in high-risk groups. This ensures a substantial and consistent demand for H1N1 vaccines. Secondly, hospital pharmacies possess the necessary infrastructure and expertise to store and administer vaccines efficiently, adhering to stringent regulatory standards. This instills confidence in patients and healthcare providers alike, boosting the credibility of hospital pharmacies as reliable sources for vaccination. Additionally, hospitals often collaborate with government health agencies and insurance providers, facilitating wider access and affordability for patients. This, in turn, further solidifies their dominance in the H1N1 vaccines market. Lastly, hospitals can leverage their established healthcare networks to conduct outreach and vaccination campaigns, driving greater vaccination coverage and ultimately exerting a significant influence over the market's dynamics.
Regional Insights
In 2022, North America commands a substantial market share in the H1N1 vaccines sector, and this trend is expected to persist during the forecast period. This expectation is rooted in the region's proactive governmental efforts to prevent H1N1 infections and its well-developed research infrastructure. As per data from the Centers for Disease Control (CDC), roughly 8 percent of the U.S. population falls ill with influenza, leading to approximately 31.4 million doctor visits and 200,000 hospitalizations during each flu season. Furthermore, ongoing technological advancements in the field of vaccines, coupled with the presence of a robust healthcare infrastructure, are acting as catalysts for significant growth in the overall regional market.
Key Market Players
AstraZeneca PLC
Sanofi Pasteur MSD AG
GSK PLC
Abbott Laboratories Inc
CSL Ltd
Pfizer Inc
CPL Biologicals Pvt Ltd
Mitsubishi Tanabe Pharma Corp
Sinovac Biotech Co Ltd
Zydus Lifesciences Ltd
Report Scope:
In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- H1N1 Vaccines Market, By Route of Administration:
- Intradermal Vaccines
- Intramuscular Vaccines
- Intranasal Vaccines
- H1N1 Vaccines Market, By Type of Brand:
- Agripal
- Fiuarix
- Influgen
- Influvac
- Nasovac
- Vaxigrip
- H1N1 Vaccines Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- H1N1 Vaccines Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.
Available Customizations:
Global H1N1 Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL H1N1 VACCINES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Product Market Map
5.3.1. By Route of Administration
5.3.2. By Type of Brand
5.3.3. By Distribution Channel
5.3.4. By Region
6. NORTH AMERICA H1N1 VACCINES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
6.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States H1N1 Vaccines Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Type of Brand
6.3.1.2.3. By Distribution Channel
6.3.2. Canada H1N1 Vaccines Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Type of Brand
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico H1N1 Vaccines Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Type of Brand
6.3.3.2.3. By Distribution Channel
7. EUROPE H1N1 VACCINES MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
7.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany H1N1 Vaccines Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Type of Brand
7.3.1.2.3. By Distribution Channel
7.3.2. United Kingdom H1N1 Vaccines Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Type of Brand
7.3.2.2.3. By Distribution Channel
7.3.3. France H1N1 Vaccines Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Type of Brand
7.3.3.2.3. By Distribution Channel
7.3.4. Italy H1N1 Vaccines Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Type of Brand
7.3.4.2.3. By Distribution Channel
7.3.5. Spain H1N1 Vaccines Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Type of Brand
7.3.5.2.3. By Distribution Channel
8. ASIA-PACIFIC H1N1 VACCINES MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
8.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China H1N1 Vaccines Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Type of Brand
8.3.1.2.3. By Distribution Channel
8.3.2. Japan H1N1 Vaccines Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Type of Brand
8.3.2.2.3. By Distribution Channel
8.3.3. India H1N1 Vaccines Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Type of Brand
8.3.3.2.3. By Distribution Channel
8.3.4. Australia H1N1 Vaccines Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Type of Brand
8.3.4.2.3. By Distribution Channel
8.3.5. South Korea H1N1 Vaccines Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Type of Brand
8.3.5.2.3. By Distribution Channel
9. SOUTH AMERICA H1N1 VACCINES MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
9.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil H1N1 Vaccines Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Type of Brand
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina H1N1 Vaccines Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Type of Brand
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia H1N1 Vaccines Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Type of Brand
9.3.3.2.3. By Distribution Channel
10. MIDDLE EAST AND AFRICA H1N1 VACCINES MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
10.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa H1N1 Vaccines Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Type of Brand
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia H1N1 Vaccines Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Type of Brand
10.3.2.2.3. By Distribution Channel
10.3.3. UAE H1N1 Vaccines Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Type of Brand
10.3.3.2.3. By Distribution Channel
10.3.4. Kuwait H1N1 Vaccines Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Route of Administration
10.3.4.2.2. By Type of Brand
10.3.4.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
14.6.1. AstraZeneca PLC
14.6.2. Sanofi Pasteur MSD AG
14.6.3. GSK PLC
14.6.4. Abbott Laboratories Inc
14.6.5. CSL Ltd
14.6.6. Pfizer Inc
14.6.7. CPL Biologicals Pvt Ltd
14.6.8. Mitsubishi Tanabe Pharma Corp
14.6.9. Sinovac Biotech Co Ltd
14.6.10. Zydus Lifesciences Ltd
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL H1N1 VACCINES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Product Market Map
5.3.1. By Route of Administration
5.3.2. By Type of Brand
5.3.3. By Distribution Channel
5.3.4. By Region
6. NORTH AMERICA H1N1 VACCINES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
6.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States H1N1 Vaccines Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Route of Administration
6.3.1.2.2. By Type of Brand
6.3.1.2.3. By Distribution Channel
6.3.2. Canada H1N1 Vaccines Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Route of Administration
6.3.2.2.2. By Type of Brand
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico H1N1 Vaccines Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Route of Administration
6.3.3.2.2. By Type of Brand
6.3.3.2.3. By Distribution Channel
7. EUROPE H1N1 VACCINES MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
7.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany H1N1 Vaccines Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Route of Administration
7.3.1.2.2. By Type of Brand
7.3.1.2.3. By Distribution Channel
7.3.2. United Kingdom H1N1 Vaccines Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Route of Administration
7.3.2.2.2. By Type of Brand
7.3.2.2.3. By Distribution Channel
7.3.3. France H1N1 Vaccines Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Route of Administration
7.3.3.2.2. By Type of Brand
7.3.3.2.3. By Distribution Channel
7.3.4. Italy H1N1 Vaccines Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Route of Administration
7.3.4.2.2. By Type of Brand
7.3.4.2.3. By Distribution Channel
7.3.5. Spain H1N1 Vaccines Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Route of Administration
7.3.5.2.2. By Type of Brand
7.3.5.2.3. By Distribution Channel
8. ASIA-PACIFIC H1N1 VACCINES MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
8.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China H1N1 Vaccines Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Route of Administration
8.3.1.2.2. By Type of Brand
8.3.1.2.3. By Distribution Channel
8.3.2. Japan H1N1 Vaccines Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Route of Administration
8.3.2.2.2. By Type of Brand
8.3.2.2.3. By Distribution Channel
8.3.3. India H1N1 Vaccines Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Route of Administration
8.3.3.2.2. By Type of Brand
8.3.3.2.3. By Distribution Channel
8.3.4. Australia H1N1 Vaccines Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Route of Administration
8.3.4.2.2. By Type of Brand
8.3.4.2.3. By Distribution Channel
8.3.5. South Korea H1N1 Vaccines Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Route of Administration
8.3.5.2.2. By Type of Brand
8.3.5.2.3. By Distribution Channel
9. SOUTH AMERICA H1N1 VACCINES MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
9.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil H1N1 Vaccines Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Route of Administration
9.3.1.2.2. By Type of Brand
9.3.1.2.3. By Distribution Channel
9.3.2. Argentina H1N1 Vaccines Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Route of Administration
9.3.2.2.2. By Type of Brand
9.3.2.2.3. By Distribution Channel
9.3.3. Colombia H1N1 Vaccines Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Route of Administration
9.3.3.2.2. By Type of Brand
9.3.3.2.3. By Distribution Channel
10. MIDDLE EAST AND AFRICA H1N1 VACCINES MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
10.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa H1N1 Vaccines Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Route of Administration
10.3.1.2.2. By Type of Brand
10.3.1.2.3. By Distribution Channel
10.3.2. Saudi Arabia H1N1 Vaccines Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Route of Administration
10.3.2.2.2. By Type of Brand
10.3.2.2.3. By Distribution Channel
10.3.3. UAE H1N1 Vaccines Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Route of Administration
10.3.3.2.2. By Type of Brand
10.3.3.2.3. By Distribution Channel
10.3.4. Kuwait H1N1 Vaccines Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Route of Administration
10.3.4.2.2. By Type of Brand
10.3.4.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. PORTER’S FIVE FORCES ANALYSIS
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. COMPETITIVE LANDSCAPE
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
14.6.1. AstraZeneca PLC
14.6.2. Sanofi Pasteur MSD AG
14.6.3. GSK PLC
14.6.4. Abbott Laboratories Inc
14.6.5. CSL Ltd
14.6.6. Pfizer Inc
14.6.7. CPL Biologicals Pvt Ltd
14.6.8. Mitsubishi Tanabe Pharma Corp
14.6.9. Sinovac Biotech Co Ltd
14.6.10. Zydus Lifesciences Ltd
15. STRATEGIC RECOMMENDATIONS
16. ABOUT US & DISCLAIMER
